Search company, investor...

Founded Year

2005

Stage

Acquired | Acquired

Total Raised

$69.02M

Valuation

$0000 

About SentreHEART

SentreHEART offers physicians precise control of remotely delivered suture for closure through developments in catheter technology and engineering expertise in remote suture delivery and tissue closure. The LARIAT Suture Delivery Device is indicated for suture placement and knot tying in surgical procedures where soft tissues are being approximated and/or ligated with a pre-tied polyester suture.

Headquarters Location

300 Saginaw Drive

Redwood City, California, 94063,

United States

650-354-1200

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo
You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo

SentreHEART Patents

SentreHEART has filed 48 patents.

The 3 most popular patent topics include:

  • Cardiac anatomy
  • Cardiac arrhythmia
  • Cardiac electrophysiology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/4/2019

7/19/2022

Cardiac anatomy, Cardiac arrhythmia, Cardiac electrophysiology, Cardiology, Cardiac procedures

Grant

Application Date

4/4/2019

Grant Date

7/19/2022

Title

Related Topics

Cardiac anatomy, Cardiac arrhythmia, Cardiac electrophysiology, Cardiology, Cardiac procedures

Status

Grant

Latest SentreHEART News

Atrial Appendage Occluder Market at 23.6% CAGR to Hit US$ 8,193.0 Million by 2033 | According to FMI

Sep 20, 2023

| According to FMI The Atrial Appendage Occluder Market is poised for substantial growth, with a projected valuation of US$ 983.5 million in 2023 set to surge to an impressive US$ 8,193.0 million by 2033. Anticipated sales of atrial appendage occluders are forecasted to experience a remarkable compound annual growth rate (CAGR) of 23.6% throughout the forecast period. The left atrial appendage (LAA), also known as the atrial appendage, is an ear-shaped pouch situated in the upper left chamber of the human heart, the left atrium. Regardless of its structure, the function of LAA is unknown. Individuals with arrhythmic cardiovascular diseases, such as atrial fibrillation, may have blood accumulation in the LAA, resulting in the production of blood clots that, if they enter the bloodstream, can cause deadly strokes. Claim Your Report – Featuring Captivating Visuals Inside! To avoid such difficulties, in addition to oral anticoagulants, an occluder can be used to permanently block off the LAA. Atrial appendage occlusion, which includes inserting a plug into the appendage, is a potential approach for protecting patients’ cardiovascular health. According to a recent study published in the journal Clinical Medical Insights: Cardiology, atrial fibrillation affects about 2% of the global population, with the disease’s incidence expected to rise fivefold over the next four decades, particularly in the United States due to its growing elderly population. Atrial Appendage Occluder Market: Drivers and Restraints The increased number of cardiovascular patients diagnosed with thromboembolism and atrial fibrillation worldwide is driving the global market for Atrial Appendage Occluders. Sedentary lifestyles and accompanying diseases such as diabetes, obesity, and hypertension have further increased demand for such devices, paving the way for market expansion. However, the restricted usage of LAA occluders in patients at high risk of stroke and bleeding while on anticoagulant medication may limit market expansion. Furthermore, the implantation and removal of the device can result in complications such as tissue erosion, which may necessitate open-heart surgery, restricting market growth. Furthermore, unfavorable laws governing endocardial LAA closure have stifled industry expansion. Atrial Appendage Occluder Market: Overview With only a few competitors, the global Atrial Appendage Occluder market is extremely consolidated. According to the World Health Organisation (WHO), over 15 million strokes occur worldwide each year. In 2010, the US spent around $53.9 billion on health care services, medications, and lost work days due to a heart attack. Ischemic strokes, which occur when blood circulation to the brain is disrupted, account for approximately 87% of all strokes. Stroke is the third leading cause of death and the leading cause of long-term disability. Atrial fibrillation is responsible for around 20% of ischemic strokes. Click Here to Request Methodology! Atrial Appendage Occluder Market: Region-wise Outlook North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, and the Middle East and Africa are the geographical segments of the Atrial Appendage Occluder Market. The North American market now leads the global industry, owing mostly to its vast elderly population. Atrial Appendage Occluder Market: Key Players The key players in the global Atrial Appendage Occluder Market include Appriva Medical Inc., Boston Scientific, St. Jude Medical, SentreHEART Inc, pfm medical ag., Occlutech, W. L. Gore & Associates, Inc., Cardia, Inc. and AtriCure, Inc. Key Segments Profiled In The Atrial Appendage Occluder Industry Survey Type of indication: Endocardial

SentreHEART Frequently Asked Questions (FAQ)

  • When was SentreHEART founded?

    SentreHEART was founded in 2005.

  • Where is SentreHEART's headquarters?

    SentreHEART's headquarters is located at 300 Saginaw Drive, Redwood City.

  • What is SentreHEART's latest funding round?

    SentreHEART's latest funding round is Acquired.

  • How much did SentreHEART raise?

    SentreHEART raised a total of $69.02M.

  • Who are the investors of SentreHEART?

    Investors of SentreHEART include AtriCure, U.S. Venture Partners, Prospect Venture Partners, Vivo Capital, Deerfield Management and 3 more.

  • Who are SentreHEART's competitors?

    Competitors of SentreHEART include Cerapedics, Svelte Medical Systems, MedShape, Celonova Biosciences, Transcend Medical and 11 more.

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Compare SentreHEART to Competitors

Glevel Logo
Glevel

GLevel is a seed stage partnership between Three Arch Partners and Incept which is a syndicate of medical device entrepreneurs and clinicians starting new opportunities in the medical device space.

s
synecor

synecor is a medical device developer

C
C2C

C2C is a medical device company developing a portfolio of medical devices.

C
Cardiola

Cardiola have designed a patented device, the m.pulse device designed to treat chronic heart failure (CHF), non-surgically, in a patient's home.

N
NeuroTrax

NeuroTrax is a medical device and technology company.

L
LinguaFlex

Linguaflex is a medical device company with a patent pending technology to treat obstructive sleep apnea. LinguaFlex's LTR is implanted and designed to be comfortable, therefore addressing the lack of compliance as an issue in the successful treatment of OSA.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.